Cargando…

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flanigan, Jaclyn, Deshpande, Hari, Gettinger, Scott
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943196/ https://www.ncbi.nlm.nih.gov/pubmed/20859451

Ejemplares similares

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
por: Zheng, Li-sheng, et al.
Publicado: (2009)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells
por: Li, Ling, et al.
Publicado: (2018)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Reply: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
por: Liu, Jiani, et al.
Publicado: (2015)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

ZD6474 in combination with paclitaxel and UVB irradiation enhances the antiproliferative effect and apoptosis on breast carcinoma
por: Sarkar, S, et al.
Publicado: (2009)

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
por: Checkley, D, et al.
Publicado: (2003)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
por: Sarkar, Siddik, et al.
Publicado: (2013)

Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse
por: Cui, Yanfen, et al.
Publicado: (2015)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway
por: Liu, Wenting, et al.
Publicado: (2022)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
por: Ahn, Jeeyun, et al.
Publicado: (2011)

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
por: Deshpande, Hari A, et al.
Publicado: (2010)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
por: Cappuzzo, F, et al.
Publicado: (2003)

Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials
por: Liu, Yuan, et al.
Publicado: (2017)

Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tian, Wei, et al.
Publicado: (2013)

The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
por: Zhou, Yan, et al.
Publicado: (2015)

Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
por: Son, Young-Min, et al.
Publicado: (2011)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Cury-Martins, Jade, et al.
Publicado: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
por: Qadir, Abdul, et al.
Publicado: (2023)

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
por: Monks, N R, et al.
Publicado: (2001)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

The Higgs as a portal to the hidden sector via an analysis of $H\to Zd_d Z_d \to 4l$ using the ATLAS detector
por: Unwuchola, D A
Publicado: (2015)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
por: Heymach, J. V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fl5mnrhi7dtua8rrd4ovnsg7oc